HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human

Immobilized HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&AFP Antibody, hFc Tag with the EC50 of 4.1 ng/ml determined by ELISA.

HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human

The purity of HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human

HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.

HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human

Immobilized HLA-A*02:01&B2M&AFP (FMNKFIYEI) TCR at 2 μg/ml (100 μl/well) on the plate. Dose response curve for HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human, His Tag with the EC50 of 26.6 ng/ml determined by ELISA.

HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human

HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human, His Tag captured on CM5 Chip via Anti-His Antibody can bind HLA-A*02:01&B2M&AFP (FMNKFIYEI) TCR with an affinity constant of 0.111 μM as determined in SPR assay (Biacore T200).

HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human

Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
Z06551
¥208,928.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer [Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and FMNKFIYEI peptide]
Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&FMNKFIYEI		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human at 1μg/ml (100μl/well) on the plate can bind Anti­HLAA*02:01&B2M&AFP (FMNKFIYEI) Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 258 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human
    • HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human

    Immobilized HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&AFP Antibody, hFc Tag with the EC50 of 4.1 ng/ml determined by ELISA.

  • HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human
    • HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human

    The purity of HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human
    • HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human

    HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.

  • HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human
    • HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human

    Immobilized HLA-A*02:01&B2M&AFP (FMNKFIYEI) TCR at 2 μg/ml (100 μl/well) on the plate. Dose response curve for HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human, His Tag with the EC50 of 26.6 ng/ml determined by ELISA.

  • HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human
    • HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human

    HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human, His Tag captured on CM5 Chip via Anti-His Antibody can bind HLA-A*02:01&B2M&AFP (FMNKFIYEI) TCR with an affinity constant of 0.111 μM as determined in SPR assay (Biacore T200).


Background
Target Background Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
Synonyms Alpha-fetoprotein; Alpha-1-fetoprotein; Alpha-feto; AFP; HPAFP; AFPD; FETA; MHC

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.